Cardax Financial Statements From 2010 to 2025
| CDXI Stock | USD 0.0001 0.00 0.00% |
Check Cardax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardax's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cardax financial statements analysis is a perfect complement when working with Cardax Valuation or Volatility modules.
Cardax |
Cardax Inc Company Shares Outstanding Analysis
Cardax's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cardax Shares Outstanding | 802.52 K |
Most of Cardax's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardax Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Cardax Inc has 802.52 K of shares currently outstending. This is 99.56% lower than that of the Pharmaceuticals sector and 99.25% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.86% higher than that of the company.
Cardax Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cardax's current stock value. Our valuation model uses many indicators to compare Cardax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardax competition to find correlations between indicators driving Cardax's intrinsic value. More Info.Cardax Inc is rated fourth in return on asset category among its peers. It is number one stock in operating margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cardax by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cardax's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Cardax Financial Statements
Investors use fundamental indicators, such as Cardax's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cardax's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Cardax Pink Sheet
Cardax financial ratios help investors to determine whether Cardax Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cardax with respect to the benefits of owning Cardax security.